Ascendis Pharma (ASND)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Endocrinesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.61% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
- Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia
- Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
- Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
- Ascendis Pharma (ASND) Authorizes $400M Share Buyback
- Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
- Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
- Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Immunogenicity Profile of Lonapegsomatropin During Long-Term Treatment in Children With Growth Hormone Deficiency. — AAPS J 2026 Sep 21 PMID 42768234
- Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. — J Immunother Cancer 2026 Sep 21 PMID 42767768
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis. — JAMA Netw Open 2026 Sep 1 PMID 42752909
- Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience. — Cancer Immunol Immunother 2026 Sep 4 PMID 42709195
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer 2026 Sep 7 PMID 42705861
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Ascendis Pharma.
Full ASND Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.